CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
2.930
+0.220 (8.12%)
At close: Nov 5, 2024, 4:00 PM
3.000
+0.070 (2.39%)
After-hours: Nov 5, 2024, 7:53 PM EST
CureVac Employees
As of December 31, 2023, CureVac had 1,172 total employees, including 999 full-time and 173 part-time employees. The number of employees increased by 123 or 11.73% compared to the previous year.
Employees
1,172
Change (1Y)
123
Growth (1Y)
11.73%
Revenue / Employee
$60,210
Profits / Employee
-$254,547
Market Cap
657.24M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,172 | 123 | 11.73% |
Dec 31, 2022 | 1,049 | 165 | 18.67% |
Dec 31, 2021 | 884 | 330 | 59.57% |
Dec 31, 2020 | 554 | 100 | 22.03% |
Dec 31, 2019 | 454 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Revance Therapeutics | 597 |
Exscientia | 483 |
Axogen | 428 |
Entrada Therapeutics | 159 |
IRADIMED CORPORATION | 148 |
Alumis | 109 |
CorMedix | 83 |
Astria Therapeutics | 59 |
CVAC News
- 1 day ago - CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - Accesswire
- 1 day ago - CureVac to Present at the 12th International mRNA Health Conference - Accesswire
- 8 days ago - CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Accesswire
- 4 weeks ago - Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents - Reuters
- 7 weeks ago - CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress - Accesswire
- 7 weeks ago - CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program - Accesswire
- 2 months ago - CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress - Accesswire
- 2 months ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update - Accesswire